Strs Ohio Sells 196,346 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Strs Ohio lessened its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 25.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 566,561 shares of the company’s stock after selling 196,346 shares during the quarter. Strs Ohio’s holdings in Teva Pharmaceutical Industries were worth $17,682,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Phoenix Financial Ltd. raised its stake in Teva Pharmaceutical Industries by 9.4% during the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after purchasing an additional 3,533,800 shares during the period. National Pension Service raised its stake in Teva Pharmaceutical Industries by 24.2% during the 3rd quarter. National Pension Service now owns 2,073,293 shares of the company’s stock valued at $41,881,000 after purchasing an additional 404,526 shares during the period. Public Sector Pension Investment Board raised its stake in Teva Pharmaceutical Industries by 11.5% during the 3rd quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock valued at $13,543,000 after purchasing an additional 69,000 shares during the period. Harel Insurance Investments & Financial Services Ltd. raised its stake in Teva Pharmaceutical Industries by 12.9% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after purchasing an additional 4,306,363 shares during the period. Finally, Teacher Retirement System of Texas raised its stake in Teva Pharmaceutical Industries by 11.2% during the 3rd quarter. Teacher Retirement System of Texas now owns 697,574 shares of the company’s stock valued at $14,091,000 after purchasing an additional 69,994 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock opened at $35.00 on Monday. The stock has a market cap of $40.24 billion, a price-to-earnings ratio of 26.31, a price-to-earnings-growth ratio of 3.23 and a beta of 0.86. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. The stock has a 50 day moving average price of $31.15 and a 200-day moving average price of $29.46. Teva Pharmaceutical Industries Ltd. has a one year low of $14.99 and a one year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The firm had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. Equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.6 EPS for the current year.

Teva Pharmaceutical Industries News Roundup

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q1 earnings beat and revenue upside driven by branded products (Austedo, Ajovy, Uzedy), which lifted investor sentiment and underpins near‑term earnings growth. Read More.
• Positive Sentiment: Multiple broker upgrades and higher price targets — UBS, Truist, JPMorgan and Piper Sandler raised targets/ratings over the last day, signaling analyst confidence in a re‑rating and further upside for the stock. Read More. Read More.
• Positive Sentiment: Teva agreed to acquire Emalex for ~\$900M to add ecopipam (paediatric Tourette’s) — a late‑stage, de‑risked asset that bolsters the specialty/innovative portfolio and supports the narrative that Teva is shifting toward higher‑margin branded growth. Read More.
• Neutral Sentiment: Teva published its 2025 Healthy Future Report and says it met all sustainability‑linked bond targets — positive for ESG profile and potentially credit metrics, but unlikely to move near‑term revenues. Read More.
• Neutral Sentiment: Blackstone put significant financing behind Teva in a recent deal — signals institutional interest/validation but primarily affects capital structure and optionality rather than immediate EPS. Read More.
• Neutral Sentiment: Industry reports list Teva among leaders in oral solid dosage contract manufacturing — positive for long‑term service demand exposure but not an immediate earnings catalyst. Read More.
• Negative Sentiment: Generics revenue remains weak even as branded sales grow — raises questions about sustainability of overall top‑line growth if branded momentum slows. Read More.
• Negative Sentiment: After a rapid share run‑up, some analysts and coverage pieces note valuation/volatility risk — investors should weigh near‑term upside from upgrades against stretched multiples and execution risk. Read More.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on TEVA shares. Wall Street Zen cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a report on Saturday. The Goldman Sachs Group raised their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, February 9th. Truist Financial raised their price target on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday. Piper Sandler restated an “overweight” rating and set a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday. Finally, Scotiabank raised their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a report on Thursday, January 29th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and an average target price of $41.56.

Insider Activity

In related news, insider Brian Savage sold 1,127 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $35,692.09. Following the completion of the sale, the insider directly owned 10,914 shares of the company’s stock, valued at approximately $345,646.38. This trade represents a 9.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark Sabag sold 62,102 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $30.14, for a total value of $1,871,754.28. Following the sale, the insider directly owned 224,940 shares of the company’s stock, valued at approximately $6,779,691.60. This trade represents a 21.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 920,901 shares of company stock worth $30,056,789 in the last three months. Corporate insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.